Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674225 | 0.79 | DYRK1A (0.53) | DYRK1AAHRTNFRIPK1MAPK1 | |
| SCHEMBL17223741 | 0.79 | PDPK1 (0.44) | DYRK1A | |
| SCHEMBL29421618 | 0.79 | PDPK1 (0.44) | DYRK1A | |
| SCHEMBL24175031 | 0.76 | NPY5R (0.46) | DYRK1AHTTMAPK1SMN1; SMN2 | |
| SCHEMBL12804489 | 0.76 | DYRK1A (0.41) | DYRK1AAHRTNFRIPK1MAPK1 | |
| SCHEMBL4838737 | 0.76 | DYRK1A (0.41) | DYRK1AAHRTNFRIPK1MAPK1 | |
| SCHEMBL4106056 | 0.72 | DYRK1A (0.50) | DYRK1AAHRTNFRIPK1CCR8 | |
| SCHEMBL31745118 | 0.72 | PIK3CA (0.31) | DYRK1ATNFRIPK1MAPK1PIK3CA | |
| SCHEMBL14641706 | 0.72 | DYRK1A (0.38) | DYRK1AAHRTNFRIPK1 | |
| SCHEMBL18194341 | 0.72 | XDH (0.51) | DYRK1AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390890-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| CN-100393722-C | Inhibitors of nucleoside metabolism | EINSTEIN COLL MED (US) | 2008-06-11 | — | — | CN | disclosed |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007069924-A1 | DEAZAPURINE ANALOGS OF 4'-AZA-L-NUCLEOSIDES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-06-21 | — | — | WO | disclosed |
| US-7211653-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2007-05-01 | — | — | US | disclosed |
| CN-1757646-A | Inhibitors of nucleoside metabolism | EINSTEIN COLL MED (US) | 2006-04-12 | — | — | CN | disclosed |
| CN-1220695-C | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN MEDICAL COLLAG (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1023308-B1 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6803455-B2 | PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-10-12 | — | — | US | disclosed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| CN-1279686-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLAGE OF MED (US) | 2001-01-10 | — | — | CN | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | DYRK1A 1535/4885HTT 1391/4885AHR 497/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | DYRK1A 2620/4885HTT 1403/4885AHR 3625/4885 |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | DYRK1A 1535/4885HTT 1391/4885AHR 497/4885 |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | CFH, NADK, UGT1A3 | DYRK1A 1576/4885HTT 888/4885AHR 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.